Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Allergan plc (AGN) Ordinary Shares EUR1

Sell:$186.31 Buy:$186.35 Change: $0.71 (0.38%)
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:$186.31
Buy:$186.35
Change: $0.71 (0.38%)
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:$186.31
Buy:$186.35
Change: $0.71 (0.38%)
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.

Contact details

Address:
Clonshaugh Business And Technology Park
DUBLIN
D17 E400
Ireland
Telephone:
+353 (21) 65235000
Website:
https://www.allergan.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AGN
ISIN:
IE00BY9D5467
Market cap:
$61.18 billion
Shares in issue:
328.28 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
Ireland
Currency:
US dollar
Indices:
n/a

Key personnel

  • Brenton Saunders
    Chairman of the Board, President, Chief Executive Officer
  • Matthew Walsh
    Chief Financial Officer, Executive Vice President
  • Karen Ling
    Chief Human Resource Officer, Executive Vice President
  • A. Robert Bailey
    Executive Vice President, Chief Legal Officer and Corporate Secretary
  • William Meury
    Executive Vice President, Chief Commercial Officer
  • C.David Nicholson
    Executive Vice President, Chief R&D Officer
  • Wayne Swanton
    Executive Vice President - Global Operations
  • James D'Arecca
    Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.